National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Riociguat (Adempas®) is indicated for the treatment of Pulmonary arterial hypertension (PAH) and Chronic thromboembolic pulmonary hypertension (CTEPH).

Rapid Review

Commenced Completed Outcome
11/04/2014 16/05/2014 Full HTA recommended at the current price.

The HSE has approved reimbursement following confidential price negotiations.